HK1199044A1 - Her3 inhibitor for modulating radiosensitivity - Google Patents

Her3 inhibitor for modulating radiosensitivity Download PDF

Info

Publication number
HK1199044A1
HK1199044A1 HK14112646.7A HK14112646A HK1199044A1 HK 1199044 A1 HK1199044 A1 HK 1199044A1 HK 14112646 A HK14112646 A HK 14112646A HK 1199044 A1 HK1199044 A1 HK 1199044A1
Authority
HK
Hong Kong
Prior art keywords
antibody
cancer
seq
group
nos
Prior art date
Application number
HK14112646.7A
Other languages
English (en)
Chinese (zh)
Inventor
．惠勒
D．L．惠勒
．黑特曼
T.黑特曼
Original Assignee
U3制药有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by U3制药有限公司 filed Critical U3制药有限公司
Publication of HK1199044A1 publication Critical patent/HK1199044A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A61N2005/1092—Details
    • A61N2005/1098—Enhancing the effect of the particle by an injected agent or implanted device
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK14112646.7A 2012-02-23 2013-02-22 Her3 inhibitor for modulating radiosensitivity HK1199044A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261602239P 2012-02-23 2012-02-23
US61/602,239 2012-02-23
PCT/EP2013/053562 WO2013124419A1 (en) 2012-02-23 2013-02-22 Her3 inhibitor for modulating radiosensitivity

Publications (1)

Publication Number Publication Date
HK1199044A1 true HK1199044A1 (en) 2015-06-19

Family

ID=47749820

Family Applications (1)

Application Number Title Priority Date Filing Date
HK14112646.7A HK1199044A1 (en) 2012-02-23 2013-02-22 Her3 inhibitor for modulating radiosensitivity

Country Status (11)

Country Link
US (2) US10357566B2 (en:Method)
EP (1) EP2817340B1 (en:Method)
JP (2) JP6207531B2 (en:Method)
KR (1) KR102051505B1 (en:Method)
CN (2) CN104136464A (en:Method)
BR (1) BR112014020666A2 (en:Method)
CA (1) CA2865256C (en:Method)
ES (1) ES2842201T3 (en:Method)
HK (1) HK1199044A1 (en:Method)
IN (1) IN2014KN01772A (en:Method)
WO (1) WO2013124419A1 (en:Method)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102316892B1 (ko) * 2019-12-20 2021-10-27 주식회사 베르티스 암의 진단용 조성물
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
TWI843989B (zh) 2021-02-19 2024-06-01 美商美威高能離子醫療系統公司 用於粒子治療系統之支架

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5183884A (en) 1989-12-01 1993-02-02 United States Of America Dna segment encoding a gene for a receptor related to the epidermal growth factor receptor
ATE188036T1 (de) * 1990-01-18 2000-01-15 Cura Nominees Pty Ltd Glykoalkaloide
US5968511A (en) 1996-03-27 1999-10-19 Genentech, Inc. ErbB3 antibodies
US6417168B1 (en) * 1998-03-04 2002-07-09 The Trustees Of The University Of Pennsylvania Compositions and methods of treating tumors
CA2332331A1 (en) * 1998-05-15 1999-11-25 Francisco Robert Treatment of human tumors with radiation and inhibitors of growth factor receptor tyrosine kinases
US20050239738A1 (en) * 2000-11-17 2005-10-27 Rupert Schmidt-Ullrich Genetic inhibition of epidermal growth factor receptor function and carcinoma cell radiosensitization
EP1283053A1 (en) 2001-08-09 2003-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Inhibitors of HER3 activity
AR056857A1 (es) 2005-12-30 2007-10-24 U3 Pharma Ag Anticuerpos dirigidos hacia her-3 (receptor del factor de crecimiento epidérmico humano-3) y sus usos
ES2377206T3 (es) * 2006-01-06 2012-03-23 Ed Geistlich Sohne Ag Fur Chemische Industrie Composiciones irradiadas y tratamiento de cánceres con radiación en combinación con taurolidina y/o taurultam
US7838495B2 (en) * 2007-04-27 2010-11-23 University Of Maryland, Baltimore Compositions and methods of use of EPB1, and ErbB3 binding protein
EP2138511A1 (en) * 2008-06-27 2009-12-30 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. HER3 as a determinant for the prognosis of melanoma
US8139714B1 (en) * 2009-06-25 2012-03-20 Velayudhan Sahadevan Few seconds beam on time, breathing synchronized image guided all fields simultaneous radiation therapy combined with hyperthermia
HUE035605T2 (en) 2009-11-13 2018-05-28 Daiichi Sankyo Europe Gmbh Material and methods for treating or preventing HER-3 associated diseases

Also Published As

Publication number Publication date
JP2017165711A (ja) 2017-09-21
US20150017096A1 (en) 2015-01-15
WO2013124419A1 (en) 2013-08-29
BR112014020666A2 (pt) 2018-09-25
KR102051505B1 (ko) 2019-12-03
US20190388540A1 (en) 2019-12-26
CN108404129A (zh) 2018-08-17
ES2842201T3 (es) 2021-07-13
CA2865256A1 (en) 2013-08-29
IN2014KN01772A (en:Method) 2015-10-23
CN104136464A (zh) 2014-11-05
CA2865256C (en) 2020-02-11
US10357566B2 (en) 2019-07-23
EP2817340B1 (en) 2020-12-09
EP2817340A1 (en) 2014-12-31
JP6207531B2 (ja) 2017-10-04
JP2015509944A (ja) 2015-04-02
KR20140123544A (ko) 2014-10-22
JP6368811B2 (ja) 2018-08-01
US11351259B2 (en) 2022-06-07

Similar Documents

Publication Publication Date Title
TWI630916B (zh) 供治療或預防人表皮生長因子受體－３（ｈｅｒ－３）相關疾病之藥料和方法
CN101939336B (zh) Axl抗体
AU2009321508B2 (en) Antibodies that specifically block the biological activity of a tumor antigen
US20120156130A1 (en) Use of her3 binding agents in prostate treatment
WO2009106096A1 (en) Treatment of resistant tumors with trifunctional antibodies
EP3271726B1 (en) Anti amphiregulin antibodies, compositions comprising same and uses thereof
JP2007523834A (ja) 癌疾患修飾抗体
US11351259B2 (en) HER3 inhibitor for modulating radiosensitivity
CN104519899A (zh) 包含e-钙粘蛋白的细胞外结构域的抑制剂的组合疗法
WO2007100920A2 (en) Diagnosis and treatment of prostate cancer
CN101553259A (zh) 显示cd63表面表达的细胞的细胞毒性介导
Ke et al. Novel monoclonal antibody against integrin α3 shows therapeutic potential for ovarian cancer
CN109476757B (zh) 抗-axl受体酪氨酸激酶抗体及其用途
WO2015108203A1 (ja) 抗ｓｌｃ６ａ６抗体を用いたがん治療用医薬組成物
Epstein et al. B7-H4 as a Target for Breast Cancer Immunotherapy
NZ711060B2 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
AU2013231846A1 (en) Combination therapies including inhibitors of the extracellular domain of E-cadherin